AB-Direct

Antibiotic distribution and recovery in tissue

Summary

Antimicrobial resistance (AMR) is on the rise, and we urgently need new antibiotics capable of beating infections that are resistant to most existing treatments. Gepotidacin is a potential antibiotic that works differently to antibiotics in use today, and lab tests suggest it could be capable of treating many resistant infections. Currently, it is under development as a treatment for two common infections where AMR is a growing problem: urogenital gonorrhoea (which is caused by Neisseria gonorrhoeae) and acute urinary tract infections caused by Escherichia coli.

Now, the AB-DIRECT project aims to explore the potential of gepotidacin as a treatment for infections caused by N. gonorrhoeae or E. coli elsewhere in the body. Their starting point for this will be tissue samples taken from patients who have received a single dose of gepotidacin before surgery to remove their tonsils or prostate. This will allow the scientists to assess the extent to which the antibiotic gets into these tissues and to evaluate different dosing levels. They will also carry out studies of the drug in animals. Ultimately, the data generated by AB-DIRECT will contribute to a decision on whether or not to run clinical trials of gepotidacin as a treatment for throat infections caused by N. gonorrhoeae or prostate infections caused by E. coli.

AB-DIRECT is part of the AMR Accelerator programme.

Participants

  Show participants on map
EFPIA companies
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Centre Hospitalier Regional Universitaire De Tours, Tours, France
  • Centre Hospitalier Universitaire De Poitiers, Poitiers, France
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Medizinische Universitaet Wien, Vienna, Austria
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Inserm Transfert SA, Paris, France
Third parties
  • Universite De Poitiers, Poitiers , France

Participants
NameIHI funding in €
Centre Hospitalier Regional Universitaire De Tours203 750
Centre Hospitalier Universitaire De Poitiers539 189
Inserm Transfert SA335 625
Institut National De La Sante Et De La Recherche Medicale877 135
Medizinische Universitaet Wien1 116 375
 
Third parties
NameFunding in €
Universite De Poitiers357 143
 
Total Cost3 429 217